Yamamoto Akihito, Kamoi Seiryu, Matsuda Shigeru, Kawase Rieko, Nakanishi Kazuho, Suzuki Shunji
Department of Obstetrics and Gynaecology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.
Medicines (Basel). 2022 Mar 30;9(4):26. doi: 10.3390/medicines9040026.
Carboplatin, the key drug used in treating gynaecological cancer, has an approximately 12-16% risk of hypersensitivity reactions. We aimed to investigate the efficacy and adverse effects of carboplatin desensitisation therapy for gynaecological cancer.
The desensitisation protocol was standardised as a four-step, 4-h, carboplatin administration in the hospital. A retrospective medical record review was conducted on 15 patients who underwent carboplatin desensitisation for gynaecological malignancies at our hospital. Patients' data were analysed to evaluate the treatment success rate, therapeutic effect of desensitisation, adverse events, and treatment.
Of 91 carboplatin desensitisation cycles scheduled; the completion rate was 93.4% (85/91). Adverse events occurred in 23 of these 91 (25.3%). In four (4.4%) of the 23 cycles, hypersensitivity reactions could be treated only by discontinuing the infusion and slowing the administration, while in the remaining 19 (20.9%), medication was administered intravenously after discontinuing the infusion to manage hypersensitivity reactions. No treatment-related deaths occurred. Overall, 23 series of anti-cancer agent regimens, including carboplatin desensitisation, were administered to the 15 patients. The therapeutic response rate was 82.6% and the disease control rate was 95.7%.
Carboplatin desensitisation was beneficial in patients with a history of carboplatin-induced hypersensitivity reactions.
卡铂是治疗妇科癌症的关键药物，发生过敏反应的风险约为12 - 16%。我们旨在研究卡铂脱敏疗法对妇科癌症的疗效和不良反应。
脱敏方案标准化为在医院进行的四步、4小时卡铂给药。对我院15例因妇科恶性肿瘤接受卡铂脱敏治疗的患者进行回顾性病历审查。分析患者数据以评估治疗成功率、脱敏治疗效果、不良事件和治疗情况。
在计划的91个卡铂脱敏周期中，完成率为93.4%（85/91）。这91个周期中有23个（25.3%）发生了不良事件。在这23个周期中的4个（4.4%），过敏反应只能通过停止输注和减慢给药速度来处理，而在其余19个（20.9%）中，在停止输注后静脉给药以处理过敏反应。未发生与治疗相关的死亡。总体而言，15例患者接受了包括卡铂脱敏在内的23个系列抗癌药物方案。治疗有效率为82.6%，疾病控制率为95.7%。
卡铂脱敏对有卡铂诱导过敏反应病史的患者有益。
